Literature DB >> 16765012

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies.

Michelle A Rudek1, Ming Zhao, Ping He, Wells A Messersmith, Sharyn D Baker.   

Abstract

A method has been developed for the quantitation of ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma. ABT-751 and metabolites were separated from endogenous material on a C18 column with acetonitrile-ammonium acetate (2 mM) mobile phase containing formic acid (0.1%, v/v) using isocratic flow for 5 min. The analytes were monitored by tandem-mass spectrometry. Calibration curves were generated over the range of 20-5,000 ng/ml for ABT-751, ABT-751 glucuronide, and ABT-751 sulfate. A 20,000 ng/ml sample that was diluted 1:10 (v/v) with plasma was accurately quantitated. The method has been successfully applied to study the plasma pharmacokinetics of ABT-751 in humans.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16765012     DOI： 10.1016/j.jpba.2006.04.010

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN： 0731-7085            Impact factor:   3.935


  5 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.

Authors:  Charles M Rudin; Ann Mauer; Martin Smakal; Rosalyn Juergens; Stanislav Spelda; Michael Wertheim; Andrew Coates; Evelyn McKeegan; Peter Ansell; Xiangdong Zhou; Jane Qian; Rajendra Pradhan; Barry Dowell; Andrew Krivoshik; Gary Gordon
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

3.  Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Authors:  Federico Innocenti; Jacqueline Ramírez; Jennifer Obel; Julia Xiong; Snezana Mirkov; Yi-Lin Chiu; David A Katz; Robert A Carr; Wei Zhang; Soma Das; Araba Adjei; Ann M Moyer; Pei Xian Chen; Andrew Krivoshik; Diane Medina; Gary B Gordon; Mark J Ratain; Leonardo Sahelijo; Richard M Weinshilboum; Gini F Fleming; Anahita Bhathena
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

4.  Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.

Authors:  Elizabeth Fox; John M Maris; Susan L Cohn; Wendy Goodspeed; Anne Goodwin; Marie Kromplewski; Diane Medina; Hao Xiong; Andrew Krivoshik; Brigitte Widemann; Peter C Adamson; Frank M Balis
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-01       Impact factor: 3.333

5.  Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.

Authors:  Michelle A Rudek; Arvind Dasari; Daniel Laheru; Ping He; Runyan Jin; Rosalind Walker; Gretchen E Taylor; Antonio Jimeno; Ross C Donehower; Manuel Hidalgo; Wells A Messersmith; W Thomas Purcell
Journal:  J Clin Pharmacol       Date:  2016-02-02       Impact factor: 3.126
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.